Related Experiment Video
Updated: May 23, 2026
08:38
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Paediatric use of mycophenolate mofetil
Heather J Downing1, Munir Pirmohamed, Michael W Beresford
1Department of Women's and Children's Health, Institute of Translational Medicine, The University of Liverpool, Alder Hey Children's NHS Foundation Trust, Eaton Road, Liverpool L12 2AP, UK.
British Journal of Clinical Pharmacology
|April 24, 2012
Summary
Mycophenolate mofetil (MMF) is increasingly used off-label in children for autoimmune conditions. Further research is needed to optimize its use and benefits in pediatric patients.
Area of Science:
- Pediatric pharmacology
- Immunosuppressive therapy
- Autoimmune disease treatment
Background:
- Many medications lack pediatric licenses for specific indications.
- Mycophenolate mofetil (MMF) use has expanded from adults to children, often off-label.
- This includes treatment for various autoimmune conditions in pediatric populations.
Purpose of the Study:
- To review the current off-label use of MMF in children.
- To examine MMF's pharmacokinetics, pharmacodynamics, and clinical applications in pediatrics.
- To identify research gaps and areas for future investigation in pediatric MMF use.
Main Methods:
- Literature review of MMF use in pediatric patients.
- Analysis of pharmacokinetic and pharmacodynamic data.
- Synthesis of clinical evidence for MMF in pediatric autoimmune conditions.
Main Results:
- MMF is utilized off-label in children for autoimmune diseases, with growing evidence of efficacy.
- Understanding of MMF's pharmacokinetics and pharmacogenomics in children is increasing.
- Despite benefits, specific pediatric trials and formal investigations are limited.
Conclusions:
- Further investigator-led studies are crucial for establishing optimal MMF dosing and efficacy in children.
- Addressing off-label use through formal research can enhance pediatric patient outcomes.
- The increasing knowledge base supports the value of dedicated pediatric MMF research.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:29Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...